Onco Wiki / Indicación

Sarcoma de Kaposi · línea 1 · Conversión de sirolimus (sarcoma de Kaposio asociado a trasplante)

Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.

Registro de base de conocimiento para la auditoría. Contenido clínico provisional: esto no es una prescripción. Un oncólogo debe verificar fuentes originales, aplicabilidad y estado de revisión.

Fuente YAML: registro completo

Notas

STUB -- new TREATMENT-intent Indication for DIS-KAPOSI (v0.3 continuation). Distinct from the pre-existing PREVENTION-intent IND-CHRONIC-HHV8-PREVENTION-IMMUNE-RESTORATION -- this Indication applies to patients with a CONFIRMED Kaposi sarcoma diagnosis. Introduces new Regimen REG-SIROLIMUS-KAPOSI-CONVERSION (reuses the existing DRUG-SIROLIMUS entity; see that Regimen's notes for the CHARTER §8.3 dosing-gap disclosure). INDEPENDENT REVIEW CORRECTION (2026-07-11): an earlier draft cited SRC-NCCN-SKIN-2025 with position "supports". That source documents only basal-cell/squamous-cell skin cancer (confirmed by direct inspection of its own KB record) -- it has no bearing on transplant immunosuppression management or mTOR-inhibitor conversion. Downgraded to "context" (loose disease-level background only, matching how dis_kaposi.yaml itself cites it) rather than removed outright, since the core clinical claim (mTOR conversion for iatrogenic KS) traces directly to the authoring narrative, not to this citation. No source in this KB currently documents the transplant-immunosuppression-conversion literature specifically -- a real, disclosed evidentiary gap. Pending two-Clinical-Co-Lead signof...

Utilizado por

Algoritmos

• ALGO-KAPOSI-1L - ALGO-KAPOSI-1L

Enfermedad

• DIS-KAPOSI - Sarcoma Kaposi

Indicación

• IND-KAPOSI-1L-CLASSIC-LOCAL-OBSERVATION - IND-KAPOSI-1L-CLASSIC-LOCAL-OBSERVATION